المصدر: PRNewsWire
وكالة أنباء
الأسهم
أهمية متوسطة
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
الرموز ذات الصلة
1
V
VNRX
VNRX
المصدر: PRNewsWire
زيارة المصدر